Form 4: iRhythm Technologies Director Karen McGinnis Receives Future RSU Grant

iRhythm Technologies, Inc. Director Karen K. McGinnis was granted 2,035 restricted stock units, which will vest over three years starting July 7, 2026.

Summary

• Karen K. McGinnis, a Director of iRhythm Technologies, Inc. (IRTC), was granted 2,035 shares of common stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this acquisition was July 7, 2025.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• The RSUs will vest in three equal annual installments of 33.33%, beginning on July 7, 2026, and continuing on each one-year anniversary thereafter.
• Vesting is contingent upon Ms. McGinnis continuing as a service provider to the company.
• Following this transaction, Ms. McGinnis beneficially owns 2,035 shares directly.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is a positive sign of alignment between management/board and shareholder interests, promoting long-term commitment. It's a standard compensation practice, indicating stability rather than significant new news, hence a moderately positive score.

Positives

• The grant of Restricted Stock Units (RSUs) to a director aligns the director's interests with long-term shareholder value, as the value of the grant is tied to the company's stock performance.
• The vesting schedule, extending over three years, encourages long-term commitment and retention of key board members.

Risks

• The vesting of the RSUs is subject to the reporting person continuing as a service provider, meaning the shares are not guaranteed if the director ceases their service.

Future Outlook

The vesting schedule for the RSUs extends into 2026 and beyond, indicating an expectation of continued service from the director and a long-term incentive structure.

Industry Context

iRhythm Technologies operates in the medical technology sector, specifically focusing on cardiac rhythm monitoring. Equity grants like RSUs are a common form of compensation for directors in this industry, aiming to align their interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to directors is a standard practice in the medical technology and broader corporate sectors for executive and board compensation.
• A vesting schedule over three years is typical for such equity grants, similar to practices at companies like Medtronic (MDT) or Boston Scientific (BSX) for their non-employee directors, ensuring long-term commitment.
• The grant price of $0 is standard for RSU grants, as they represent a right to receive shares upon vesting, rather than a purchase.

Related Party Transactions

• The RSU grant to a director is a related party transaction, which is a standard compensation practice disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, as the value of the RSUs is tied to the company's stock performance, potentially encouraging decisions that enhance long-term shareholder value.

Next Steps

• The vesting of the granted Restricted Stock Units will occur in annual installments starting July 7, 2026.

Key Dates

Recommendation

Keywords

iRhythm Technologies, IRTC, SEC Form 4, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Insider Transaction, Karen McGinnis, Stock Vesting